Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Sickle Cell Disease
Interventions
Nexplanon 68 MG Drug Implant
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed No phase listed Observational Accepts healthy volunteers Results available

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

NCT00042289
Conditions
HIV Infections
Interventions
atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
1,578 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2020
U.S. locations
39
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
Conditions
Vaginal Bleeding
Interventions
Tamoxifen Citrate 10Mg Tab, Estradiol, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
15 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Richmond, Virginia
Completed Early Phase 1 Interventional Results available

Ovarian Function With ENG Implant and UPA Use

NCT04291001
Conditions
Contraception
Interventions
ENG implant, oral ulipristal acetate
Device · Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed No phase listed Observational Accepts healthy volunteers

Long-Acting Progestin Contraception and the Vaginal Microbiome

NCT02740998
Conditions
Sexually Transmitted Infection
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Prolonged Use of IUD/Implant for Contraception

NCT02267616
Conditions
Contraception
Interventions
Etonogestrel Implant
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,076 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
2
States / cities
Indianapolis, Indiana • St Louis, Missouri
Completed Early Phase 1 Interventional

Inpatient Adolescent Contraception

NCT04423068
Conditions
Pregnancy Related, Contraception, Contraceptive Usage, Contraception Behavior, Pregnancy
Interventions
SexHealth II, Contraceptive
Behavioral · Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
14 Years to 21 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Pregnancy
Interventions
Mirena (Levonorgestrel IUS, BAY86-5028), ParaGard, Implanon/Nexplanon
Drug
Lead sponsor
Bayer
Industry
Eligibility
15 Years to 44 Years · Female only
Enrollment
13,880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Recruiting Not applicable Interventional Accepts healthy volunteers

Vapocoolant Spray to Reduce Pain With Nexplanon Insertion

NCT06933381
Conditions
Reducing Pain With Nexplanon Implant Insertion
Interventions
Vapocoolant spray, Placebo
Device · Other
Lead sponsor
Queen's Medical Center
Other
Eligibility
14 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Honolulu, Hawaii • Waimea, Hawaii
Completed No phase listed Observational Accepts healthy volunteers

Implants on Mobile Health Unit

NCT03347539
Conditions
Contraception
Interventions
Nexplaon
Device
Lead sponsor
University of Chicago
Other
Eligibility
14 Years to 19 Years · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Breastfeeding Etonogestrel Implant Study

NCT03978598
Conditions
Contraception
Interventions
Etonogestrel, Nexplanon
Drug · Device
Lead sponsor
University of New Mexico
Other
Eligibility
13 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
2
States / cities
Albuquerque, New Mexico • Salt Lake City, Utah
Completed Not applicable Interventional Accepts healthy volunteers

Home or Office Visit for the Insertion of Implantable Birth Control

NCT01816932
Conditions
Contraception
Interventions
Home Visit, Office visit
Procedure
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
ESI-related Bleeding
Interventions
Doxycycline, Placebo
Drug
Lead sponsor
Petra M. Casey
Other
Eligibility
18 Years to 51 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Completed No phase listed Observational Accepts healthy volunteers

Contraceptive Hormones, Immunity, and Microbiome Evaluation

NCT03660046
Conditions
Hormonal Contraception
Interventions
Depot medroxyprogesterone acetate (DMPA), Etonogestrel implant (Eng-Implant), Levonorgestrel IUD (Lng-IUD)
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 45 Years · Female only
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
Opiate Addiction, Pregnancy, Contraceptive Behavior, Sexual Behavior
Interventions
Nexplanon (etonogestrel contraceptive implant), Standard postpartum contraceptive care
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Topiramate on Etonogestrel Concentrations in Contraceptive Implant Users

NCT03335163
Conditions
Migraine, Migraine;Menstrual, Contraception
Interventions
Topiramate
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Drug Interaction
Interventions
Efavirenz
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Shoulder Contraceptive Implant Study

NCT04463693
Conditions
Contraception
Interventions
Etonogestrel implant
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Contraception, Bleeding
Interventions
Ulipristal Acetate, Placebo oral capsule
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Contraception, Breastfeeding, Postpartum Contraception
Interventions
Etonogestrel Contraceptive Implant
Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
17 Years to 45 Years · Female only
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Contraception
Interventions
Blood draw
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Nexplanon and Combined Oral Contraceptive (COC) Combined Use Study

NCT02852265
Conditions
Contraception
Interventions
Etonogestrel contraceptive implant
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
16 Years to 35 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Sacramento, California
Conditions
Contraception
Interventions
ethinyl estradiol/etonogestrel vaginal ring, ethinyl estradiol/norelgestromin transdermal contraceptive
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
10
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 7 more
Conditions
Uterine Hemorrhage, Contraception
Interventions
Combined Oral Contraceptive Pill, Placebo Sugar Pill
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Aurora, Colorado